Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 2/20 | 0.62 |
| ▸ | HTR1D | P28221 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13298494 | 0.94 | HTR1B (0.63) | HTR1BHTR1DL3MBTL1KDM4EMAPT | |
| SCHEMBL24307302 | 0.87 | HTR1D (0.49) | HTR1BHTR1DHRH3 | |
| SCHEMBL23067890 | 0.86 | DRD2 (0.60) | L3MBTL1KDM4EMAPTLMNAALDH1A1 | |
| SCHEMBL10895841 | 0.85 | ALDH1A1 (0.64) | HTR1BHTR1DL3MBTL1LMNAALDH1A1 | |
| SCHEMBL5929490 | 0.83 | MAPT (0.62) | L3MBTL1KDM4EMAPTLMNAALDH1A1 | |
| SCHEMBL9124449 | 0.82 | HTR1B (0.60) | HTR1BHTR1DL3MBTL1KDM4ELMNA | |
| SCHEMBL19632708 | 0.82 | HTR1B (0.60) | HTR1BHTR1DL3MBTL1KDM4ELMNA | |
| SCHEMBL26126465 | 0.82 | HTR1B (0.60) | HTR1BHTR1DL3MBTL1KDM4ELMNA | |
| SCHEMBL17308303 | 0.82 | MAPT (0.54) | L3MBTL1KDM4EMAPTLMNAALDH1A1 | |
| SCHEMBL20172578 | 0.82 | HTR1B (0.55) | HTR1BHTR1DL3MBTL1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345785-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | BIO RAD LABORATORIES INC (US) | 2025-11-13 | — | — | US | claimed |
| US-11896969-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | BIO-RAD LABORATORIES, INC. (US) | 2024-02-13 | — | — | US | claimed |
| US-20250345785-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | BIO RAD LABORATORIES INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12364978-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | BIO-RAD LABORATORIES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240261775-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | BIO-RAD LABORATORIES, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11896969-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | BIO-RAD LABORATORIES, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-3660004-B1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2021046284-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | BIO-RAD LABORATORIES, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| US-20210069692-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | BIO-RAD LABORATORIES, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20210069692-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | BIO-RAD LABORATORIES, INC. | 2021-03-11 | — | — | US | disclosed |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-20 | — | — | US | disclosed |
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2017197488-A1 | LIBRARIES OF DIVERSE MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CYCLENIUM PHARMA INC. (CA) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017030814-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-17 | — | — | US | disclosed |
| EP-2144881-B1 | ISOQUINOLINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ( COPD ) AND ASTHMA | ASTRAZENECA AB (SE) | 2012-06-20 | — | — | EP | disclosed |
| US-8012979-B2 | Compounds and their uses 707 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| WO-2011038261-A1 | HETEROCYCLIC KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008122765-A1 | NEW COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345785-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | ABCG2, SLC7A1, MSR1 | HTR1B 1932/4885HTR1D 2519/4885L3MBTL1 3154/4885 |
| US-12364978-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | ABCG2, SLC7A1, MSR1 | HTR1B 1932/4885HTR1D 2519/4885L3MBTL1 3154/4885 |
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | CYP3A7, UGT1A7, UGT2B7 | HTR1B 704/4885HTR1D 1614/4885L3MBTL1 4856/4885 |
| US-20240261775-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | ABCG2, SLC7A1, MSR1 | HTR1B 1932/4885HTR1D 2519/4885L3MBTL1 3154/4885 |
| US-20210069692-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | ABCG2, SLC7A1, MSR1 | HTR1B 1932/4885HTR1D 2519/4885L3MBTL1 3154/4885 |
| US-11896969-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | ABCG2, SLC7A1, MSR1 | HTR1B 1932/4885HTR1D 2519/4885L3MBTL1 3154/4885 |
| US-20150361042-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | HTR1B 4464/4885HTR1D 4735/4885L3MBTL1 942/4885 |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, CCNE1 | HTR1B 4011/4885HTR1D 3905/4885L3MBTL1 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.